81 related articles for article (PubMed ID: 7865123)
1. A new genetically engineered vaccine for animal growth promotion.
Xu WZ; Du NX; Li GD; Wang Y; Li ZP
Sci China B; 1994 Oct; 37(10):1234-41. PubMed ID: 7865123
[TBL] [Abstract][Full Text] [Related]
2. Construction and evaluation of the eukaryotic expression plasmid encoding two copies of somatostatin genes fused with hepatitis B surface antigen gene S.
Liang A; Cao S; Han L; Yao Y; Moaeen-Ud-Din M; Yang L
Vaccine; 2008 Jun; 26(23):2935-41. PubMed ID: 18455280
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous expression of growth hormone releasing hormone (GHRH) and hepatitis B surface antigen/somatostatin (HBsAg/SS) fusion genes in a construct in the skeletal muscle enhances rabbit weight gain.
Dai JW; Liu SC; Hao LL; Zhang YL; Zhang Q; Ren XH; Jiang QY
Anim Biotechnol; 2008; 19(2):104-16. PubMed ID: 18432401
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
5. Antigenic properties of vaccinia virus and of the virus recombinant strains expressing heterologous genes.
Chelyapov NV; Antonova TP; Yanova NN; Chernos VI
Acta Virol; 1988 Sep; 32(5):409-16. PubMed ID: 2904735
[TBL] [Abstract][Full Text] [Related]
6. [Construction and characterization of a novel somatostatin prokaryotic expression].
Liang A; Feng X; Han L; Hua G; Sang L; Liu X; Liu Y; Yang L
Sheng Wu Gong Cheng Xue Bao; 2008 Jun; 24(6):995-8. PubMed ID: 18807981
[TBL] [Abstract][Full Text] [Related]
7. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.
Berkower I; Raymond M; Muller J; Spadaccini A; Aberdeen A
Virology; 2004 Mar; 321(1):75-86. PubMed ID: 15033567
[TBL] [Abstract][Full Text] [Related]
8. [Construction and expression of somatostatin (S14) and hepatitis B surface antigen gene in yeast Pichia pastoris].
Wang Z; Gao R; Yang L; Liu S
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Sep; 19(3):483-6. PubMed ID: 12557529
[TBL] [Abstract][Full Text] [Related]
9. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
[TBL] [Abstract][Full Text] [Related]
10. The immunogenicity of recombinant LC16mO vaccinia virus harboring HBsAg gene in mice.
Watanabe K; Morita M; Sato T; Yausi K; Kojima A
Biologicals; 1991 Apr; 19(2):77-85. PubMed ID: 1888498
[TBL] [Abstract][Full Text] [Related]
11. A novel hepatitis B virus variant S 129 (Gln-->Leu): lack of correlation between antigenicity and immunogenicity.
Wu L; He JW; Yao X; Li HM; Wen YM
J Med Virol; 1999 Dec; 59(4):424-30. PubMed ID: 10534722
[TBL] [Abstract][Full Text] [Related]
12. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen.
Shiau AL; Murray K
J Med Virol; 1997 Mar; 51(3):159-66. PubMed ID: 9139078
[TBL] [Abstract][Full Text] [Related]
13. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.
Smith GL; Mackett M; Moss B
Nature; 1983 Apr; 302(5908):490-5. PubMed ID: 6835382
[TBL] [Abstract][Full Text] [Related]
14. Immune response induced by a different combined immunization of HBsAg vaccine.
Wu T; Chen M; Ou SH; Cheng T; Zhang J; Xia NS
Intervirology; 2007; 50(5):336-40. PubMed ID: 17700028
[TBL] [Abstract][Full Text] [Related]
15. Improved recombinant LC16m0 or LC16m8 vaccinia virus successfully expressing hepatitis B surface antigen.
Watanabe K; Kobayashi H; Kajiyama K; Morita M; Yasuda A; Gotoh H; Saeki S; Sugimoto M; Saito H; Kojima A
Vaccine; 1989 Feb; 7(1):53-9. PubMed ID: 2718607
[TBL] [Abstract][Full Text] [Related]
16. [New technology of vaccine production--international prospect of the development. Method and theory of production of vaccines by genetic engineering. b. Trials of development of recombinant vaccinia polyvaccines].
Yasuda A; Kojima A
Nihon Rinsho; 1987 Oct; 45(10):2342-8. PubMed ID: 3129603
[No Abstract] [Full Text] [Related]
17. Expression and purification of Dengue virus type 2 envelope protein as a fusion with hepatitis B surface antigen in Pichia pastoris.
Bisht H; Chugh DA; Swaminathan S; Khanna N
Protein Expr Purif; 2001 Oct; 23(1):84-96. PubMed ID: 11570849
[TBL] [Abstract][Full Text] [Related]
18. [Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus].
Al'tshteĭn AD; Zakharova LG; Loparev VN; Pashvykina GV; Gorodetskiĭ SI
Dokl Akad Nauk SSSR; 1985; 285(3):696-9. PubMed ID: 4092585
[No Abstract] [Full Text] [Related]
19. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent.
Kondo R; Feitelson MA; Strayer DS
Gene Ther; 1998 May; 5(5):575-82. PubMed ID: 9797861
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
